Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has land­ed a new first from UNICEF the first-ever con­tract for malar­ia vac­cines, worth up to $170 mil­lion for 18 mil­lion vac­cine dos­es dis­trib­uted over the next three years.

The vac­cine, known as Mosquir­ix or RTS,S, won WHO’s back­ing last Oc­to­ber af­ter a con­tro­ver­sial start, but UNICEF said these dos­es will po­ten­tial­ly save thou­sands of lives every year.

“We hope this is just the be­gin­ning,” Etl­e­va Kadil­li, di­rec­tor of UNICEF’s sup­ply di­vi­sion, said. “Con­tin­ued in­no­va­tion is need­ed to de­vel­op new and next-gen­er­a­tion vac­cines to in­crease avail­able sup­ply, and en­able a health­i­er vac­cine mar­ket. This is a gi­ant step for­ward in our col­lec­tive ef­forts to save chil­dren’s lives and re­duce the bur­den of malar­ia as part of wider malar­ia pre­ven­tion and con­trol pro­grammes.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.